Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.29 USD | +1.33% | +13.37% | +78.91% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 150M |
---|---|---|---|---|---|
Net income 2024 * | -34M | Net income 2025 * | -47M | EV / Sales 2024 * | - |
Net cash position 2024 * | 84.8M | Net cash position 2025 * | 51.3M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.74
x | P/E ratio 2025 * |
-3.08
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc.
1 day | +1.33% | ||
1 week | +13.37% | ||
1 month | -8.76% | ||
3 months | +53.69% | ||
6 months | +63.57% | ||
Current year | +78.91% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.29 | +1.33% | 1,170,511 |
24-05-30 | 2.26 | +6.10% | 351,315 |
24-05-29 | 2.13 | +4.16% | 353,592 |
24-05-28 | 2.045 | +1.24% | 525,292 |
24-05-24 | 2.02 | +5.21% | 206,445 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+78.91% | 150M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- RGLS Stock